GovChime
Notice ID: 1ed57b3b499b43cababd03b89ca1ee02Award NoticeAwardedArchived

NIAID CLINICAL PRODUCTS CENTER (CPC)

Awarded on April 1, 2026. Full description on SAM.gov.

Awarded tounder 75N93026C00003 (source: SAM.gov award notice)• $32.9M

Overview

Posted
March 30, 2026
Notice type
Award Notice
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIAID
Place of performance
Frederick, Maryland, 21703
Last updated
Nov 1, 2026
First published
Last updated on SAM.gov
Award date
Apr 1, 2026
Award amount (SAM.gov award notice)
$32.9M

Identifiers

Solicitation number
75N93026C00003
Notice ID
1ed57b3b499b43cababd03b89ca1ee02
Award number (PIID)
75N93026C00003

Description

A competitive cost reimbursement, level of effort (term) type contract was awarded, for the period of performance of April 1, 2026 through March 31, 2027 (Base Period), and a total period of performance (including base period and all options) of April 1, 2026 
through March 31, 2033. Upon analysis of the type of work and all associated costs involved, a fixed-price type contract was not feasible due to the absence of precise specifications and difficulties in estimating costs with accuracy. Based upon the uncertainties involved, the Government would assume undue risk in attempting to fit a relatively dynamic (science responsive and result-driven) requirement into a fixed-price environment. A fixed-price contract would be disadvantageous to the Government, since it does not provide the Government with the flexibility that is needed to responsibly shiftwith the evolving needs of the requirement.
 

Full description on SAM.gov

Award Overview

Award Number

75N93026C00003

Award Amount (SAM.gov award notice)

$32.9M

Award Date

Apr 1, 2026

Awardee

Awardee UEI

C4PUY1BKHP59

Awardee CAGE Code

313T8

Awardee Address

Frederick, MD 21703, UNITED STATES

Original Solicitation

Notice ID: 1ed57b3b499b43cababd03b89ca1ee02

Posted Date: Mar 30, 2026

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

4
  • 75N93019C00003
    EMINENT SERVICES CORP
    Department of Health and Human ServicesNAICS 541715
    $19.8MSigned Jan 29, 2026
  • 75N93019C00003
    EMINENT SERVICES CORP
    Department of Health and Human ServicesNAICS 541715
    $18.8MSigned Jun 25, 2025
  • 75N93019C00003
    EMINENT SERVICES CORP
    Department of Health and Human ServicesNAICS 541715
    $18.4MSigned Mar 14, 2025
  • 75N93019C00003
    EMINENT SERVICES CORP
    Department of Health and Human ServicesNAICS 541715
    $16.7MSigned Feb 27, 2025

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

  1. 2
    Version 2SolicitationArchived

    NIAID CLINICAL PRODUCTS CENTER (CPC)

    Notice c418c9f44b534339939d87e2d6098a32 on SAM.gov

  2. 6
    Version 6Award NoticeArchivedCurrent

    Type changed from Solicitation to Award Notice

    NIAID CLINICAL PRODUCTS CENTER (CPC)

    Notice 1ed57b3b499b43cababd03b89ca1ee02 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This is a Request for Information (RFI) for Research and Development (R&D) open to all interested organizations, regardless of business size. This is NOT a solicitation for capability statements, proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain industry input to inform requirements development and acquisition planning for the proposed research services described in the attached draft Statement of Work (SOW). The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). This RFI is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. Interested organizations are encouraged to review the attached draft SOW and respond to the information requests outlined in this notice. The Government anticipates issuing a solicitation for this requirement at a later date under a separate announcement. Issuance of this notice does not obligate the Government to issue a solicitation or award a contract.
-Special Notice11/17/2026
This is a Request for Information (RFI) for Research and Development (R&D) open to all interested organizations, regardless of business size. This is NOT a solicitation for capability statements, proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain industry input to inform requirements development and acquisition planning for the proposed research services described in the attached draft Statement of Work (SOW). The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). This RFI is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. Interested organizations are encouraged to review the attached draft SOW and respond to the information requests outlined in this notice. The Government anticipates issuing a solicitation for this requirement at a later date under a separate announcement. Issuance of this notice does not obligate the Government to issue a solicitation or award a contract.
-Special Notice11/17/2026
Randomized Controlled Trial of a Novel Clinical Decision Support Tool for Individualized Exercise Recommendations in Breast Cancer Survivors.
-Pre-Solicitation11/25/2026
This is a Small Business Sources Sought (SBSS) Notice for Research and Development (R&D). This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of qualified small businesses under the size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the small business size standard for such requirements is 1,000 employees or less, including applicable affiliates. This SBSS notice is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The purpose of this synopsis is to identify small business organizations with requisite qualifications to provide the services stated herein. Based on capability statements received in response to this Sources Sought Announcement, this acquisition may be solicited as a small business set-aside. All small business organizations (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) are encouraged to respond to this notice. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice.
-Market Research11/23/2026
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit."
-Solicitation12/08/2026

Additional Details

Solicitation Number

75N93026C00003

Archive Date

Apr 16, 2026

Office Address

BETHESDA, MD, 20892